Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial by Skudicky, Daniel et al.
Relationship Between Treatment-Induced Changes in Left
Ventricular Mass and Blood Pressure in Black African
Hypertensive Patients
Results of the Baragwanath Trial
Daniel Skudicky, MD; Pinhas Sareli, MD; Elena Libhaber, MSc; Geoffrey Candy, MSc;
Ivo Radevski, MD; Zdravska Valtchanova, MD; Elizabeth Tshele, RN; Lutgarde Thijs, MSc;
Ji-Guang Wang, MD; Jan A. Staessen, MD
Background—In a single-center study, we compared to what extent changes in conventional and ambulatory blood
pressure (BP) predicted regression of left ventricular mass (LVM) index in response to antihypertensive treatment in
previously untreated and treated patients with sustained hypertension.
Methods and Results—We enrolled 173 black African patients who, off treatment, had a daytime diastolic BP ranging
from 90 to 114 mm Hg. Antihypertensive drugs were titrated and combined to reduce the daytime diastolic BP below
90 mm Hg. Echocardiograms were obtained at baseline and follow-up. Mean systolic/diastolic clinic BP, 24-hour BP,
and LVM index were similar in previously untreated (n64) and previously treated (n109) patients and averaged
171/102 mm Hg, 151/97 mm Hg, and 118 g/m2, respectively. At 4 months, these values had decreased (P0.001) by
26/12 mm Hg, 23/14 mm Hg, and 14 g/m2 in previously untreated patients and by 22/9 mm Hg, 21/13 mm Hg, and 19
g/m2 in previously treated patients. In the previously untreated patients, the regression in LVM index correlated to a
similar degree (P0.09) with the decreases in the conventional (r0.34; P0.005) and the 24-hour (r0.26; P0.04)
systolic BP. In the previously treated patients, the corresponding correlations were 0.02 (P0.82) and 0.10 (P0.32),
respectively. Compared with the 24-hour systolic BP, automated oscillometric measurements of systolic BP obtained at
the clinic yielded similar results.
Conclusions—In previously untreated patients with sustained hypertension followed at a single center, reductions in clinic
and ambulatory systolic pressure in response to antihypertensive treatment equally predicted the regression in LVM
index. (Circulation. 2002;105:830-836.)
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Left ventricular hypertrophy is a strong and independentpredictor of cardiovascular morbidity and mortality1–3
both in hypertensive patients and in the general population. It
is associated with a higher risk of myocardial infarction,
stroke, sudden death, and death from any cause. Furthermore,
echocardiographically determined left ventricular mass
(LVM) confers prognostic information beyond that provided
by traditional risk factors, including hypertension.1 Moreover,
recent studies4,5 and 3 meta-analyses6–8 on antihypertensive
treatment showed that the reduction in LVM correlated with
the decrease in blood pressure (BP). However, controversy
still exists with regard to what type of BP measurement
(conventional, automated, or ambulatory) correlates better
with changes in LVM induced by antihypertensive treat-
ment.4 Most previous studies did not exclude previously
treated or white-coat hypertensive patients or were multicen-
tric, which makes clinic measurements of BP more difficult to
standardize. In older patients with isolated systolic hyperten-
sion, active treatment compared with placebo reduced elec-
trocardiographic voltages only in patients with sustained
hypertension and not in those with white-coat hypertension.5
The Baragwanath Hypertension Study was a single-center,
randomized trial that compared several drug classes to initiate
treatment in black African patients with sustained hyperten-
sion confirmed by ambulatory BP monitoring.9 In the present
analysis, we compared to what extent changes in conven-
tional and automated BP readings at the clinic and in the
ambulatory BP predicted regression of LVM index in re-
sponse to antihypertensive treatment in previously untreated
or treated patients with sustained hypertension.
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Methods
Subjects and Procedures
The Baragwanath Hypertension Study was a single-center, random-
ized, open-label trial conducted at the Chris Hani-Baragwanath
Hospital from 1994 through 1997. The protocol was approved by the
Committee for Research on Human Subjects of the University of
Witwatersrand. Black men and women could be enrolled if they were
18 to 70 years of age and free of clinically significant cardiovascular
or noncardiovascular disorders. Women of reproductive age had to
use adequate contraception. All patients gave informed written
consent.
Patients diagnosed as being hypertensive after a 2-week placebo
run-in period and with a count of returned placebo tablets within
80% to 120% of the expected number qualified for randomization if,
in addition, their daytime diastolic BP was 90 to 114 mm Hg.
Eligible patients were randomized to nifedipine gastrointestinal
therapeutic system (GITS) 30 mg/d, verapamil slow release (SR) 240
mg/d, hydrochlorothiazide 12.5 mg/d, or enalapril 10 mg/d.9 Patients
were followed up at monthly intervals. The target BP was a daytime
diastolic pressure of 90 mm Hg. If at the first monthly follow-up
visit the target was not reached, the daily dose of the first-line drug
was increased, as follows: nifedipine GITS to 60 mg, verapamil SR
to 360 mg, hydrochlorothiazide to 25 mg, and enalapril to 20 mg. At
2 months, patients of the nifedipine GITS group who had not
achieved the target BP were additionally randomized to 1 of the
following 4 treatment strategies: the addition of enalapril (10 mg/d),
carvedilol (25 mg/d), or verapamil SR (120 mg/d) or increasing the
daily dose of nifedipine GITS to 90 mg. In the uncontrolled patients
of the verapamil SR group, the daily dose of the calcium-channel
blocker could be increased to 480 mg. Patients not controlled on
hydrochlorothiazide 25 mg/d received reserpine 0.125 mg/d, and
those not controlled on enalapril 20 mg/d were given hydrochloro-
thiazide 12.5 mg/d.
All patients randomized in the Baragwanath Trial underwent
echocardiography at baseline. However, only patients in whom
high-quality echocardiograms could be obtained were eligible for
inclusion in the echocardiographic substudy.
BP Measurements
At baseline and at each of 4 follow-up visits, BP was assessed with
3 techniques. First, after the patient had rested in the sitting position
for 10 minutes, the study nurse measured the conventional BP 3
times consecutively according to the recommendations of the Amer-
ican Heart Association.10 The same nurse performed the conven-
tional BP readings in all patients. Subsequently, the sitting BP was
recorded 10 times consecutively at 3-minute intervals using cali-
brated Dinamap 1846 SX oscillometric monitors (Critikon Inc).11
For analysis, the 3 conventional and 10 Dinamap automated BP
measurements were averaged.
Furthermore, oscillometric SpaceLabs 90207 devices12
(SpaceLabs Inc) were programmed to obtain BP readings every 15
minutes from 6:00 AM to 10:00 PM and every 30 minutes from 10:00
PM to 6:00 AM. The intraindividual BP means were weighted by the
time interval between successive BP readings. For analysis, the
daytime period was defined as the time interval from 6:00 AM to 6:00
PM and nighttime ranged from 10:00 PM to 4:00 AM. Previous studies
in black Africans have shown that this definition excludes the rapid
BP changes in the morning and evening.9
Echocardiography
At randomization and at 4 months, M-mode, 2-dimensional, pulse
and color Doppler echocardiograms were obtained with a Hewlett-
Packard Sonos 2500 system using a 2.5-MHz transducer. M-mode
echocardiography of the left ventricle was performed in the short-
axis view. M-mode variables were analyzed according to the
American Society of Echocardiography Convention13 and included
left ventricular end-diastolic and end-systolic diameters and septal
and posterior wall thickness. All measurements were recorded on
videotape and analyzed by the same experienced echocardiographer
who was blinded to the BP and the clinic data of the patients. For
statistical analysis, measurements were averaged over 3 heart cycles.
Doppler estimation of the stroke volume was assessed as previously
described.14 LVM was adjusted for body size according to an
anatomically validated regression method.15 Replicate measurements
of LVM index showed that in the present study population, the
interobserver and intraobserver coefficients of variation were 12.4%
and 11.4%, respectively.
Statistical Analysis
Database management and statistical analysis were performed with
SAS software, version 6.12 (SAS Institute Inc). Previously untreated
and treated patients were compared using Student’s t test and the 2
statistic for continuous measurements and class variables, respec-
tively. Single and stepwise multiple regression analyses were used to
analyze the relationship between changes in LVM or LVM index and
various explanatory variables, including the treatment-induced BP
changes. Multivariate ANOVA was performed to test the null
hypothesis of no differences between the parameters of regression
equations.16
Results
Baseline Demographic Characteristics
Of the 409 patients randomized in the trial, 233 (57%) were
eligible for inclusion in the present substudy because echo-
cardiograms of sufficient quality had been obtained. Of the
latter patients, 23 (10%) had been withdrawn at 4 months and
37 (16%) did not have all measurements at baseline or at 4
months required for the statistical measurements. Thus, our
study includes 173 patients who, compared with the 236
nonparticipants, had similar BP values at entry (Table 1).
However, nonparticipants were older, more obese, and in-
cluded slightly more previously treated patients (46% versus
37%, respectively, P0.052)
The 173 patients (41 men and 132 women) were 5110
years of age. Their body-mass index averaged 30.36.2
kg/m2. Of the 173 patients, 109 had previously been treated,
and 85 patients had been on monotherapy either with diuret-
ics (n48), angiotensin-converting enzyme inhibitors
(n20), -methyldopa (n9), or calcium channel blockers
(n8). Furthermore, 17 patients had been on multiple drugs,
including diuretics in 11 patients, and 7 patients could not
report which drug treatment they had been taking before the
screening visit. Compared with the untreated patients, the
previously treated patients included more women and had
higher mean body-mass index (Table 1). At entry, clinic,
Dinamap and ambulatory BP values (Table 2) as well as all
echocardiographic measurements (Table 3) were similar in
previously untreated and treated patients (P0.04).
Results in Previously Untreated Patients
The number of patients who remained on monotherapy was
27 of 39 in the nifedipine group, 6 of 9 in the verapamil SR
group, 2 of 8 in the enalapril group, and 4 of 8 in the
hydrochlorothiazide group.
At 4 months, compared with baseline, BP measured at the
clinic by the study nurse or by the Dinamap device had
significantly (P0.001) decreased (Table 2). In addition,
there was a parallel shift (P0.001) of the systolic and
diastolic ambulatory BP profiles to lower values (Figure 1
and Table 2). The treatment-induced changes in the BP
recorded oscillometrically, either at the clinic or over 24
hours, were significantly correlated with the corresponding
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changes in the conventionally measured office readings
(Figure 2).
After 4 months of antihypertensive therapy, LVM and
LVM index had decreased (P0.001) by 24 g and 14 g/m2,
respectively (Table 3). This was achieved through a reduction
in wall thickness with no significant change in left ventricular
end-diastolic diameter. Both before and after standardization
for body surface area, there was a positive linear relationship
between the decrease in LVM index and the reduction in
systolic BP as assessed by conventional or automated mea-
surement at the clinic or by 24-hour ambulatory monitoring
(Table 4). The corresponding relationship for diastolic pres-
sure was not statistically significant (Table 4). Considering
conventional, Dinamap, and 24-hour BP measurements, there
were no significant differences in the regression parameters
relating the changes in LVM to those in BP (P0.09). These
findings remained unaltered when LVM index was used as an
outcome variable (Figures 3 and 4). In addition, measurement
of the 24-hour or Dinamap BP did not significantly increase
the accuracy of the prediction of the changes in LVM
(P0.40) or LVM index (P0.37) over and beyond that
already provided by conventional systolic pressure.
Results in Previously Treated Patients
The number of patients that remained on monotherapy was 40
of 65 in the nifedipine group, 14 of 17 in the verapamil SR
group, 3 of 14 in the enalapril group, and 5 of 13 in the
hydrochlorothiazide arm. There were no significant differ-
ences in the use of study medications between previously
untreated and treated patients (P0.42). Furthermore, at 4
months, the clinic, Dinamap, and ambulatory BP (Table 2 and
Figure 1) had fallen to the same extent as in the previously
untreated group. After 4 months of antihypertensive therapy
with the study medications, LVM and LVM index had
decreased by 34 g (P0.001) and 19 g/m2 (P0.001),
respectively (Table 3). This was achieved through a reduction
TABLE 1. Clinical Characteristics at Randomization of Participants and Nonparticipants
Nonparticipants
Participants
Previously
Untreated
Previously
Treated
All
Included
No. 236 64 109 173
Age, y 5510 4911 529 5110*
Female sex, n (%) 181 (77) 40 (62.5) 92 (84.4)‡ 132 (76)
Body mass index, kg/m2 31.87 28.46 31.46‡ 30.36.2†
Systolic/Diastolic BP, mm Hg
Conventional 17318/1037 17017/1039 17221/1029 17221/1029
Dinamap 16618/998 16216/1007 16521/1008 16521/1008
24-Hour 15015/967 14915/967 15315/977 15315/977
Daytime 15514/1027 15315/1027 15814/1037 15814/1037
Nighttime 13918/8510 14018/8610 14320/8711 14320/8711
Values are meanSD.
*P0.001 and †P0.03, significance of the difference between participants and nonparticipants; ‡P0.002,
significance of the difference between previously untreated and previously treated patients.
TABLE 2. Conventional, Dinamap, and Ambulatory BP at Baseline and
at 4 Months
BP, mm Hg Baseline 4 Months Change
Previously untreated
(n64)
Conventional 17017/1039 14421/9111 2625/1214
Dinamap 16216/1007 13719/8810 2521/1211
24-Hour 14915/967 12614/9218 2315/149
Daytime 15315/1027 13014/878 2316/159
Nighttime 14018/8610 11917/7310 2116/1310
Previously treated
(n109)
Conventional 17221/1029 15022/9311 2227/914
Dinamap 16521/1008 14320/9011 2226/1012
24-Hour 15315/977 13214/859 2117/1310
Daytime 15814/1037 13515/9010 2217/1310
Nighttime 14320/8711 12417/7510 1919/1212
All changes in blood pressure were significant (P0.001).
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in wall thickness and left ventricular end-diastolic diameter.
Treatment-induced changes in all echocardiographic mea-
surements were similar (P0.18) in previously untreated and
treated patients (Table 3). However, in contrast to the
previously untreated group, in treated patients, all correla-
tions between the changes in LVM index and any type of BP
measurement failed to reach statistical significance (Table 4
and Figure 3). Adjustment for previous treatment with diuret-
ics or other drugs did not alter these findings.
Discussion
The Baragwanath Hypertension Study was a single-center
trial that investigated the efficacy of various drug classes to
initiate antihypertensive treatment in black African patients.9
The same trained research nurse obtained all conventional BP
readings. Only patients with sustained hypertension were
enrolled. The study medications were titrated or combined to
reduce the daytime diastolic BP to a level below 90 mm Hg.
Four months of antihypertensive treatment significantly low-
ered clinic, 24-hour, daytime, and nighttime BP, which led to
a significant decrease in wall thickness, LVM, and LVM
index.
We found significant and positive correlations between the
changes in LVM index and all types of systolic BP in
response to treatment in previously untreated patients,
whereas in previously treated patients these correlations were
nonsignificant. Furthermore, in untreated patients, regression
of LVM index was not significantly better correlated with the
reduction in 24-hour, daytime, or nighttime systolic pressure
than with the decrease in the conventional systolic pressure.
The latter observations are at variance with 2 previous
studies. In the Study on Ambulatory Monitoring of Blood
Figure 1. Systolic and diastolic BP profiles at
baseline (open symbols) and at 4 months
(closed symbols). Values are hourly BP means
with 95% CIs. Results are given separately for
previously untreated and treated patients.
TABLE 3. Echocardiographic Data at Baseline and 4 Months
Characteristic Baseline 4 Months Change P
Previously untreated (n64)
LVEDD, mm 47.04.9 46.44.6 0.65.1 0.34
PWT, mm 11.10.21 10.31.7 0.72.1 0.007
IVS, mm 11.92.3 11.01.7 0.92.2 0.003
MWT, mm 11.52.1 10.71.4 0.81.9 0.001
LVM, g 20555 18140 24.242.9 0.001
LVM index, g/m2 11833 10423 14.326.1 0.001
Stroke volume, mL 7316 7418 0.099 0.32
Previously treated (n109)
LVEDD, mm 45.76.3 43.95.8 1.86.4 0.004
PWT, mm 11.52.3 10.71.8 0.82.3 0.001
IVS, mm 12.62.0 11.61.9 1.02.0 0.001
MWT, mm 12.01.9 11.21.6 0.91.8 0.001
LVM, g 21270 17855 33.752.6 0.001
LVM index, g/m2 11834 9926.1 18.629.1 0.001
Stroke volume, mL 7317 7316 0.00008 0.96
LVEDD indicates left ventricular end-diastolic diameter; PWT, posterior wall end-diastolic
thickness; IVS, interventricular septum end-diastolic thickness; and MWT, end-diastolic mean wall
thickness.
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Pressure and Lisinopril Evaluation (SAMPLE),17 after 12
months of follow-up of 184 patients, the decreases in systol-
ic/diastolic pressure were 26/18 mm Hg for the clinic pres-
sure and 18/12 mm Hg for the 24-hour pressure. LVM index
decreased from 158 to 133 g/m2. The reduction in LVM index
was not correlated with the changes in the clinic BP (r0.11/
0.11), but it was significantly (P0.01) correlated with the
changes in the 24-hour BP (r0.42/0.38). In the study by
Fagard et al,4 during 6 months of follow-up of 54 patients, the
reductions in systolic/diastolic BP were 22/16 mm Hg for the
conventional pressure, 19/12 mm Hg for Dinamap measure-
ments performed at the clinic, and 17/11 mm Hg for the
24-hour BP. LVM decreased from 237 to 212 g. Changes in
LVM were significantly related to changes in systolic BP.
The correlation coefficients, adjusted for sex and body size,
amounted to 0.39 and 0.40 for the conventional and auto-
mated measurements of clinic systolic pressures, respec-
tively, and to 0.55 for the 24-hour systolic pressure. The
24-hour systolic pressure added 7.4% (P0.05) and 6.2%
(P0.06) to the variance of the changes in LVM explained in
Figure 2. Relationships in 64 previ-
ously untreated patients between
changes in 24-hour (d 24h) or
Dinamap (d Din) measurements of
systolic BP (SBP) and diastolic BP
(DBP) and the corresponding changes
in the conventionally measured BPs (d
Con).
TABLE 4. Regression Coefficients Between Changes in LVM Index and in BP
Over 4 Months
Systolic Pressure Diastolic Pressure
Regression Coefficient
(95% CI) P
Regression Coefficient
(95% CI) P
Previously untreated
(n64)
Conventional 0.37 (0.14 to 0.61) 0.004 0.14 (0.32 to 0.60) 0.56
Dinamap 0.34 (0.05 to 0.63) 0.03 0.42 (0.12 to 0.97) 0.13
24-Hour 0.46 (0.03 to 0.89) 0.04 0.60 (0.013 to 1.34) 0.11
Daytime 0.34 (0.05 to 0.73) 0.10 0.42 (0.27 to 1.10) 0.24
Nighttime 0.40 (0.01 to 0.81) 0.06 0.55 (0.06 to 1.17) 0.08
Previously treated
(n109)
Conventional 0.02 (0.18 to 0.23) 0.82 0.05 (0.45 to 0.34) 0.80
Dinamap 0.06 (0.28 to 0.15) 0.57 0.21 (0.66 to 1.24) 0.37
24-Hour 0.17 (0.48 to 0.14) 0.32 0.17 (0.73 to 0.39) 0.56
Daytime 0.19 (0.50 to 0.12) 0.23 0.22 (0.75 to 0.30) 0.41
Nighttime 0.09 (0.38 to 0.20) 0.54 0.53 (0.39 to 0.48) 0.98
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terms of the conventional and automated measurements of
clinic systolic pressures, respectively.
The discordance between our findings and the 2 previous
studies may depend on various factors, such as the charac-
teristics of the study participants, duration of follow-up under
treatment with study medications, precision and standardiza-
tion of the conventional BP readings, and recruitment of
previously treated patients. Our earlier studies demonstrated
that under antihypertensive treatment, LVM decreased to a
similar extent in white patients and black African pa-
tients.18,19 Furthermore, previous studies showed that 3
months of antihypertensive treatment is sufficient to maxi-
mally reduce LVM.20,21 However, a recent analysis of the
Losartan Intervention For Endpoint Reduction (LIFE) study22
suggested that maximum effect on left ventricular hypertro-
phy of antihypertensive treatment may not be achieved for at
least 2 years. The results of the Prospective Randomized
Enalapril Study Evaluating Regression of Left Ventricular
Enlargement (PRESERVE) trial23 will undoubtedly shed
more light on this issue. In the SAMPLE study, the 12-month
change in LVM index correlated equally with the change in
the 24-hour systolic pressure in previously untreated
(r0.49) and previously treated (r0.39) patients, whereas
such relationships were not observed for the changes in the
clinic BP. However, the clinic BP in the SAMPLE study was
the average of only 2 conventional readings, which were
obtained by different observers across 11 centers. Conven-
tional BP readings are more difficult to standardize in
multicenter studies. In our study, only one study nurse
measured the clinic BP at baseline and follow-up in all
patients. The strength of the reported associations of LVM
index with conventional BP readings has varied greatly,
with correlation coefficients ranging from close to zero24
to approximately 0.5.25 Fagard et al26 produced convincing
evidence suggesting that differences among studies may be
partly attributable to the variable degrees of standardiza-
tion and the divergent number of conventional BP
readings.
Figure 3. Partial correlation coefficients with
95% CIs between changes in LVM index
and changes in BP after 4 months of treat-
ment with the study medications in 64 previ-
ously untreated and 109 previously treated
patients.
Figure 4. Relationships between the changes in LVM index (LVMI) and in systolic BP (SBP) as assessed by 3 techniques of BP mea-
surement in 64 previously untreated patients. d Con indicates conventional measurement; d Din, Dinamap; and d 24 h, 24-hour.
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In the Baragwanath Trial, all patients had a daytime
diastolic BP ranging from 90 to 114 mm Hg. Patients with
white-coat hypertension were therefore excluded. In the 2
previous studies,4,17 patients were exclusively selected on the
basis of conventional BP readings at the clinic. Furthermore,
depending on the number of clinic visits, the number of
conventional BP readings averaged to diagnose hypertension,
and the level of the conventional BP, the prevalence of
white-coat hypertension among patients with elevated clinic
pressure on conventional measurement may range from 5%27
to 70%.28 In white-coat hypertensive patients, the clinic BP
does not reflect the usual BP load and therefore may be
expected to be only weakly correlated or not correlated with
LVM. We hypothesize that the high degree of standardization
of the conventional BP measurements in the clinic and the
exclusion of white-coat hypertensive patients explain why in
our previously untreated patients, in contrast to earlier stud-
ies, the correlations between the changes in LVM and in
systolic BP were of similar magnitude for all types of BP
measurement.
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